Other Information.
+Added: Trading Plans or Rule 10b5-1 Trading Plans
+Added: During the quarter ended September 30, 2025, our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated the contracts, instructions or written plans for the purchase or sale of our securities set forth in the table below.
+Added: Date of Adoption/
+Added: Type of Trading Arrangement
+Added: Expiration Date
+Added: Total Shares of Common Stock to be Sold***
+Added: Non-Rule 10b5-1**
+Added: Chief Operating and Financial Officer
+Added: February 3, 2025
+Added: Up to 150,000
+Added: Chief Operating and Financial Officer
+Added: Termination (3)
+Added: September 10, 2025 (4)
+Added: Up to 150,000
+Added: * Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
+Added: ** "Non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K under the Exchange Act.
+Added: *** Represents the maximum number of shares that may be sold pursuant to the 10b5-1 trading arrangement.
+Added: The number of shares to be sold was dependent on the satisfaction of certain conditions as set forth in the written plan.
+Added: (1) We inadvertently omitted from Item 5 of Part II of our Quarterly Report on Form 10-Q for the quarterly period ending March 31, 2025, the disclosure of the adoption of a contract, instruction or written plan for the purchase or sale of our securities.
+Added: (2) This plan was intended to qualify as a “Rule 10b5-1 trading arrangement” as defined in Item 408(a) of Regulation S-K.
+Added: However, the plan did not comply with the cooling-off period required by Exchange Act Rule 10b5-1(c) and is therefore deemed a “Non-Rule 10b5-1 trading arrangement”.
+Added: (3) This contract, instruction, or written plan was subsequently terminated on September 10, 2025, as disclosed above, prior to the completion of any sales under the plan.
+Added: (4) Represents the termination of a written plan originally adopted on February 3, 2025 that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
Incorporated by Reference
1 unchanged sentence
Amended and Restated Bylaws.
−Removed: Olema Pharmaceuticals, Inc.
−Removed: Amended and Restated Non-Employee Director Compensation Policy
−Removed: Second Amendment to Loan and Security Agreement by and between the Registrant and Silicon Valley Bank, a division of First-Citizens Bank & Trust Company, dated June 27, 2025
Certification of Chief Executive Officer Pursuant to Rules 13a‑14(a) and 15d‑14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
6 unchanged sentences
* Filed herewith.
−Removed: # Indicates management contract or compensatory plan or arrangement
The certifications attached as Exhibit 32.1 accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C.
2 unchanged sentences
Olema Pharmaceuticals, Inc.
−Removed: August 11, 2025
+Added: November 10, 2025
/s/ Sean Bohen, M.D., Ph.D.
2 unchanged sentences
( Principal Executive Officer )
−Removed: August 11, 2025
+Added: November 10, 2025
/s/ Shane Kovacs
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.